- Home
- ADNT vs NVCR Comparison
ADNT vs NVCR Comparison
Compare ADNT & NVCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ADNT | NVCR |
|---|---|---|
| Founded | 2016 | 2000 |
| Country | Ireland | Switzerland |
| Employees | N/A | N/A |
| Industry | Auto Parts:O.E.M. | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.5B |
| IPO Year | 2016 | 2015 |
Fundamental Metrics
Financial Performance| Metric | ADNT | NVCR |
|---|---|---|
| Price | $19.76 | $12.06 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 10 | 6 |
| Target Price | $24.85 | ★ $28.08 |
| AVG Volume (30 Days) | 716.9K | ★ 2.6M |
| Earning Date | 05-05-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 21.79 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $17,439,000,000.00 | $655,353,000.00 |
| Revenue This Year | $2.76 | $7.72 |
| Revenue Next Year | $2.47 | $6.74 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 7.56 | ★ 8.28 |
| 52 Week Low | $10.04 | $9.82 |
| 52 Week High | $27.32 | $20.05 |
Technical Indicators
Market Signals| Indicator | ADNT | NVCR |
|---|---|---|
| Relative Strength Index (RSI) | 28.00 | 46.12 |
| Support Level | $18.47 | $10.86 |
| Resistance Level | $19.93 | $14.13 |
| Average True Range (ATR) | 0.81 | 0.99 |
| MACD | -0.53 | -0.10 |
| Stochastic Oscillator | 1.94 | 24.61 |
Price Performance
Historical ComparisonAbout ADNT Adient plc
Adient began trading Oct. 31, 2016, when Johnson Controls spun off its automotive experience segment. Adient is a leading seating supplier to the industry with about a midteens share of the global market including unconsolidated joint venture business. Its share in China is around 20%, down from about 45%, following the sale of its main joint venture there at the end of fiscal 2021. Unconsolidated revenue from joint ventures was about $3.5 billion in fiscal 2025 and consolidated China revenue was $1.3 billion. The company is headquartered in Ireland but has corporate offices in the Detroit area. Fiscal 2025 (Sept. 30 year-end) consolidated revenue, which excludes joint venture sales, was $14.5 billion.
About NVCR NovoCure Limited
NovoCure Ltd is an oncology company with a propreitary platform technology in United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis and other products and technologies for the treatment of Glioblastoma, Non-smell cell lung cancer and Pancreatic cancer. Geographically, the company derives majority of its revenue from the United States and rest from Germany, Japan and other markets.